Alnylam CEO Maraganore To Step Aside At End Of 2021

Founding CEO will remain involved with Alnylam’s scientific advisory board, while current president/COO Yvonne Greenstreet will move up to the chief executive’s office.

John Maraganore, CEO of Alnylam
CEO John Maraganore said he'll hand off Alnylam's top job at the end of 2021

Alnylam CEO John Maraganore is stepping down at the end of the year, having taken the company from concept to commercial stage over nearly 20 years. The news overshadowed other updates during Alnylam Pharmaceuticals Inc.’s third quarter 2021 earnings call on 28 October.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Executives On The Move

More from Leadership

Merck & Co. CMO Eliav Barr Assures On Pipeline As Keytruda LOE Looms Large

 

Chief medical officer Eliav Barr, responsible for overseeing clinical development, talked to Scrip in an interview at Merck’s headquarters about the company’s pipeline diversification.

GSK: Blenrep’s Return Is Just The Start Of Our Oncology Renaissance

 

GSK’s antibody-drug conjugate looks set for a blockbuster future in multiple myeloma after an approval in the UK, and the company’s head of oncology says it is already planning for the next generation of therapies.

Executives On The Move: Ten CMOs And Three CEOs and CFOs Each Among This Week’s Changes

Recent moves in the industry include C-suite changes at Dyne Therapeutics, City Therapeutics and ProQR Therapeutics, plus Madrigal Pharmaceuticals acquires chief medical officer from Novartis.